IL312030A - Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof - Google Patents
Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereofInfo
- Publication number
- IL312030A IL312030A IL312030A IL31203024A IL312030A IL 312030 A IL312030 A IL 312030A IL 312030 A IL312030 A IL 312030A IL 31203024 A IL31203024 A IL 31203024A IL 312030 A IL312030 A IL 312030A
- Authority
- IL
- Israel
- Prior art keywords
- benzimidazole
- mutated
- acting
- crystal forms
- cdk9 inhibitor
- Prior art date
Links
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 title 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
- C07C65/10—Salicylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255562P | 2021-10-14 | 2021-10-14 | |
| PCT/US2022/078143 WO2023064920A1 (en) | 2021-10-14 | 2022-10-14 | Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312030A true IL312030A (en) | 2024-06-01 |
Family
ID=84272325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312030A IL312030A (en) | 2021-10-14 | 2022-10-14 | Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250011298A1 (enExample) |
| EP (1) | EP4416139A1 (enExample) |
| JP (1) | JP2024539631A (enExample) |
| KR (1) | KR20240115816A (enExample) |
| CN (1) | CN118355006A (enExample) |
| AU (1) | AU2022362075A1 (enExample) |
| CA (1) | CA3234907A1 (enExample) |
| IL (1) | IL312030A (enExample) |
| MX (1) | MX2024004515A (enExample) |
| WO (1) | WO2023064920A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220079851A (ko) * | 2019-09-11 | 2022-06-14 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk 억제제 및 약제로서의 이의 용도 |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2025189114A1 (en) | 2024-03-08 | 2025-09-12 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220079851A (ko) | 2019-09-11 | 2022-06-14 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk 억제제 및 약제로서의 이의 용도 |
-
2022
- 2022-10-14 KR KR1020247015784A patent/KR20240115816A/ko active Pending
- 2022-10-14 AU AU2022362075A patent/AU2022362075A1/en active Pending
- 2022-10-14 MX MX2024004515A patent/MX2024004515A/es unknown
- 2022-10-14 IL IL312030A patent/IL312030A/en unknown
- 2022-10-14 WO PCT/US2022/078143 patent/WO2023064920A1/en not_active Ceased
- 2022-10-14 EP EP22802453.5A patent/EP4416139A1/en not_active Withdrawn
- 2022-10-14 US US18/700,928 patent/US20250011298A1/en active Pending
- 2022-10-14 CA CA3234907A patent/CA3234907A1/en active Pending
- 2022-10-14 CN CN202280081352.7A patent/CN118355006A/zh active Pending
- 2022-10-14 JP JP2024522235A patent/JP2024539631A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240115816A (ko) | 2024-07-26 |
| CA3234907A1 (en) | 2023-04-20 |
| EP4416139A1 (en) | 2024-08-21 |
| WO2023064920A1 (en) | 2023-04-20 |
| JP2024539631A (ja) | 2024-10-29 |
| AU2022362075A1 (en) | 2024-05-09 |
| MX2024004515A (es) | 2024-07-01 |
| CN118355006A (zh) | 2024-07-16 |
| US20250011298A1 (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL312030A (en) | Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof | |
| EP4368625A4 (en) | SHP2 INHIBITOR AND ITS USE | |
| EP4524136A4 (en) | KINESIN INHIBITOR KIF18A AND ITS USE | |
| EP4067351A4 (en) | Diazaindole derivative and use thereof as chk1 inhibitor | |
| PL4011881T3 (pl) | Postacie krystaliczne inhibitora atr i ich zastosowanie | |
| IL284226A (en) | Novel polymorphic forms of a tgfb inhibitor | |
| EP4434979A4 (en) | KIF18A INHIBITOR | |
| DK3964510T3 (da) | Krystalform af wee1-hæmmerforbindelse og anvendelse deraf | |
| EP4400499A4 (en) | GLUTARIMIDE COMPOUND AND ITS USE | |
| PL3788044T3 (pl) | Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania | |
| IL287768A (en) | Kcnt1 inhibitors and methods of use | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| HRP20260295T1 (hr) | Kristalni oblici inhibitora btk | |
| EP4148050A4 (en) | Novel acid secretion inhibitor and use thereof | |
| EP4450501A4 (en) | CDK9 INHIBITOR AND ITS USAGE | |
| IL308750A (en) | Novel salts and crystals | |
| IL299840A (en) | Inhibitors of complement factors and uses thereof | |
| EP3741758A4 (en) | BROMODOMAIN INHIBITOR COMPOUND AND ITS USE | |
| IL299700A (en) | Kcnt1 inhibitors and methods of use | |
| EP4168398A4 (en) | TYK-2 INHIBITOR | |
| EP4333821A4 (en) | SARS-COV-2 INHIBITORS | |
| IL310931A (en) | 6-aza-quinoline derivatives and related uses | |
| EP3981768A4 (en) | POLYMORPH OF A CDK9 INHIBITOR, METHOD FOR PREPARING THE POLYMORPH AND USE THEREOF | |
| EP4244205A4 (en) | IRE1ALPHA INHIBITORS AND THEIR USES | |
| EP4161917A4 (en) | GRK2 INHIBITORS AND THEIR USES |